| |
| |
|
| Insider
Information: |
Lowe Christopher P. |
| Relationship: |
Interim CEO, COO & CFO |
| City: |
Mountain View |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
413,915 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$298,819 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
413,915 |
|
|
| Total
Value |
$298,819 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
4
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-4.0
|
0.0
|
| Percentage
Gain/Loss : |
 -35.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Anthera Pharmaceuticals Inc |
ANTH |
|
2013-03-25 |
108,915 |
2011-10-25 |
0 |
Premium* |
|
|
Hansen Medical Inc |
HNSN |
Interim CFO, Director |
2016-07-27 |
0 |
2010-04-30 |
0 |
Premium* |
|
|
Vincerx Pharma, Inc |
VINC |
Director |
2022-08-25 |
40,000 |
2021-06-29 |
0 |
Premium* |
|
|
Cortexyme, Inc. |
CRTX |
Interim CEO, COO & CFO |
2022-03-03 |
265,000 |
2021-06-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VINC |
Vincerx Pharma, Inc |
Director |
– • – |
2022-08-25 |
4 |
B |
$1.65 |
$19,139 |
D/D |
11,600 |
40,000 |
2.39 |
% |
|
| VINC |
Vincerx Pharma, Inc |
Director |
– • – |
2022-08-24 |
4 |
B |
$1.65 |
$30,299 |
D/D |
18,400 |
28,400 |
2.39 |
% |
|
| CRTX |
Cortexyme, Inc. |
Interim CEO, COO & CFO |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
265,000 |
0 |
- |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-10-05 |
4 |
AS |
$98.50 |
$488,856 |
D/D |
(4,963) |
60,000 |
0 |
% |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-10-05 |
4 |
OE |
$54.85 |
$272,221 |
D/D |
4,963 |
64,963 |
0 |
- |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-08-17 |
4 |
OE |
$2.23 |
$66,900 |
D/D |
30,000 |
60,000 |
0 |
- |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-08-16 |
4 |
AS |
$94.23 |
$2,096,779 |
D/D |
(22,000) |
30,000 |
0 |
% |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-08-16 |
4 |
OE |
$2.23 |
$49,060 |
D/D |
22,000 |
52,000 |
0 |
- |
|
| VINC |
Vincerx Pharma, Inc |
Director |
– • – |
2021-06-30 |
4 |
B |
$12.66 |
$45,576 |
D/D |
3,600 |
10,000 |
2.39 |
% |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-06-30 |
4 |
OE |
$2.23 |
$66,900 |
D/D |
30,000 |
30,000 |
0 |
- |
|
| VINC |
Vincerx Pharma, Inc |
Director |
– • – |
2021-06-29 |
4 |
B |
$12.59 |
$80,576 |
D/D |
6,400 |
6,400 |
2.39 |
% |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-06-28 |
4 |
AS |
$53.39 |
$1,083,074 |
D/D |
(20,000) |
0 |
0 |
% |
|
| CRTX |
Cortexyme, Inc. |
COO & Chief Financial Officer |
• – – |
2021-06-28 |
4 |
OE |
$2.23 |
$44,600 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| HNSN |
Hansen Medical Inc |
Interim CFO |
• • – |
2016-07-27 |
4 |
D |
$4.00 |
$417,000 |
D/D |
(104,250) |
0 |
0 |
- |
|
| HNSN |
Hansen Medical Inc |
Interim CFO |
• • – |
2016-07-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
104,250 |
0 |
- |
|
| HNSN |
Hansen Medical Inc |
Interim CEO |
• • – |
2014-05-20 |
4 |
B |
$1.44 |
$28,890 |
D/D |
20,000 |
42,500 |
2.81 |
- |
|
| HNSN |
Hansen Medical Inc |
Director |
– • – |
2013-05-13 |
4 |
B |
$1.52 |
$19,000 |
D/D |
12,500 |
22,500 |
2.39 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
CFO and Chief Business Officer |
• – – |
2013-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
67,579 |
108,915 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
C.F.O. and C.B.O. |
• – – |
2013-01-03 |
4 |
D |
$0.69 |
$5,975 |
D/D |
(8,660) |
41,336 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
C.F.O. and C.B.O. |
• – – |
2012-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
18,845 |
49,996 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Chief Financial Officer & CBO |
• – – |
2011-11-03 |
4 |
AS |
$6.88 |
$103,236 |
D/D |
(15,000) |
46,151 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Chief Financial Officer & CBO |
• – – |
2011-10-25 |
4 |
AS |
$7.07 |
$32,784 |
I/I |
(4,637) |
0 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Chief Financial Officer & CBO |
• – – |
2011-08-08 |
4 |
OE |
$1.34 |
$13,400 |
D/D |
10,000 |
61,151 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Chief Financial Officer & CBO |
• – – |
2011-08-03 |
4 |
AS |
$6.88 |
$100,432 |
D/D |
(14,600) |
51,151 |
0 |
- |
|
| ANTH |
Anthera Pharmaceuticals I... |
Chief Financial Officer & CBO |
• – – |
2011-08-02 |
4 |
AS |
$7.28 |
$36,571 |
I/I |
(5,000) |
4,637 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
